A Study to Investigate the Effect of Food on the Bioavailability of a Capsid Inhibitor (CAI) in Male and Female Healthy Participants

Inclusion Criteria:

• Participants who are 18 to 55 years of age.

• Participants who are overtly healthy.

• One SARs-CoV-2 negative test is required prior to dosing

• Body weight within 50-100 kg and body mass index (BMI) within the range 19-32 kg/m2 (inclusive).

• Capable of giving signed informed consent.

• Participants male at birth must use male condoms, and participants female at birthwho are of childbearing potential must be using acceptable forms of birth control.

Exclusion Criteria:

• History or presence of disorders capable of significantly altering the absorption,metabolism, or elimination of drugs.

• Current or chronic liver disease, hepatic or biliary abnormalities, or relevanthepatitis.

• Abnormal blood pressure.

• Any malignancy within the past 5 years except certain localized malignancies, orbreast cancer within the past 10 years. Participants with exclusionaryelectrocardiogram findings.Positive HIV test or ongoing behaviors that put theparticipant at high risk for HIV acquisition.

• Participants who are breastfeeding or plan to become pregnant during the study.

• Past or intended use of exclusionary medications or vaccines.

• Exposure to >4 new investigational products within 12 months, previous participationin this study, or current enrolment or participation in another investigationalstudy.

• ALT >1.5x upper limit of normal (ULN), total bilirubin >1.5x ULN, and/or estimatedserum creatinine clearance <60 mL/min.

• History of or current infection with hepatitis B or hepatitis C.

• Positive SARS-CoV-2 test, having signs and symptoms suggestive of COVID-19, orcontact with known COVID-19 positive person.

• Positive HIV antibody test.

• Participants with positive results for illicit drug use, regular use of drugs ofabuse, tobacco or nicotine-containing product use, and/or excessive alcohol use.